Multiple myeloma during pregnancy as a challenge in clinical practice – a review
| Main Authors: | Szydełko, Magdalena, Szydełko, Joanna, Litwińczuk, Michał |
|---|---|
| Format: | Article Journal |
| Terbitan: |
, 2019
|
| Subjects: | |
| Online Access: |
https://zenodo.org/record/3408437 |
Daftar Isi:
- Szydełko Magdalena, Szydełko Joanna, Litwińczuk Michał. Multiple myeloma during pregnancy as a challenge in clinical practice – a review. Journal of Education, Health and Sport. 2019;9(8):920-937. eISNN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.3408437 http://ojs.ukw.edu.pl/index.php/johs/article/view/7453 The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019. © The Authors 2019; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 05.07.2019. Revised: 25.07.2019. Accepted: 14.09.2019. Multiple myeloma during pregnancy as a challenge in clinical practice – a review Magdalena Szydełko1a, Joanna Szydełko2b, Michał Litwińczuk2c 1Medical Student, I Faculty of Medicine with Dentistry Division, Medical University of Lublin, Poland 2Department of Endocrinology, Medical University of Lublin, Poland amszydelko@interia.pl, ORCID ID: https://orcid.org/0000-0001-6216-9934 bjszydelko@interia.pl, ORCID ID: https://orcid.org/0000-0003-3744-9058 cmlitwinczuk405@gmail.com, ORCID ID: https://orcid.org/0000-0002-4086-6779 Corresponding author: Joanna Szydełko Department of Endocrinology Jaczewskiego 8 Street 20-954 Lublin, Poland phone: +48 81 72 44 668 e-mail: jszydelko@interia.pl Key words: multiple myeloma, pregnancy, symptoms, diagnosis, therapeutic strategies Abstract Introduction: Multiple myeloma (MM) is a hematological malignancy characterized by an abnormal proliferation and accumulation of monoclonal plasma cells. MM typically affects the elderly people with the median age at the diagnosis between 65 to 74 years. Only in < 2% of cases it is observed <40 years, that is why its incidence in gestation is extraordinary. Aim of the study: The aim of this study was to present the review of the literature concerning the cases of MM in pregnancy as a great challenge in clinical practice. Moreover, the most common symptoms, diagnostic as well as therapeutic strategies of MM in pregnancy were discussed. The influence of the status of the newborns and the pregnant women were also analyzed. Description of knowledge: Our overview revealed 44 cases of MM in pregnancy. It was predominantly diagnosed in the 2nd or 3rd trimester and the median age of women was 34 years. The caesarean section seemed to be the recommended method of delivery and the mean gestational age at the delivery was 35. hbd. Nearly all of the newborns were born premature, but healthy. The symptoms were similar to those in the general population (bone pain, signs of anemia, hypercalcemia) and in single cases the renal failure, hypertensive or bilateral breast lumps were observed. Steroids were predominantly administered and the therapy based on cyclophosphamide, urethane or interferon was the rarity. Conclusions: MM in pregnancy seems not be a contraindication for maintaining of gestation. The management may be problematic due to the lack of guidelines concerning the methods of treatment as well as its safety for the fetus. Based on the literature, steroids are the most certain and efficient anti-MM drugs in pregnancy. However, the majority of newborns are premature, which is also associated with the possibility of later complications.